Genentech weighs slow-walking ovarian cancer therapy; Yogurt instead of colonoscopies?

Genentech's CEO said the company may slow the development of an ovarian cancer therapy to make more money under drug pricing reform.

August 11, 2023 Check out STAT+

Sponsored By

Genentech STAT+ | Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform Genentech is considering slow-walking an ovarian cancer therapy to make more money under drug pricing reform. By Rachel Cohrs STAT+ | A yogurt drink instead of a colonoscopy? Study uses engineered bacteria to detect cancer A proof-of-concept study shows that DNA-slurping bacteria can identify cancerous sequences, advancing hope of a gentler form of diagnostics. By Angus Chen Opinion: Public pharma is the best solution to the ongoing problem of drug shortages Publicly accountable public agencies can assure resilient supply chains and offer medicines at or even below cost. By Dana Brown and Christopher Morten

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser